Califf Admits Hard To Navigate Biosimilars Without Guides
This article was originally published in Scrip
Executive Summary
Robert Califf, the new commissioner of the FDA, admitted during a March 2 Senate hearing that if the agency doesn't get its pending biosimilars guidances out soon, "it's going to be difficult for people to navigate and know what they need to do."